These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 21858589)
1. A randomized controlled trial of conventional fraction and late course accelerated hyperfraction three-dimensional conformal radiotherapy for esophageal cancer. Wang JH; Lu XJ; Zhou J; Wang F Cell Biochem Biophys; 2012 Jan; 62(1):107-12. PubMed ID: 21858589 [TBL] [Abstract][Full Text] [Related]
2. [Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma]. Sheng W; Feng XZ; Han JQ Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):702-6. PubMed ID: 22340054 [TBL] [Abstract][Full Text] [Related]
3. Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: a phase III randomized study. Zhao KL; Shi XH; Jiang GL; Yao WQ; Guo XM; Wu GD; Zhu LX Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1014-20. PubMed ID: 15990003 [TBL] [Abstract][Full Text] [Related]
4. Late-course accelerated hyperfractionated radiotherapy for localized esophageal carcinoma. Zhao KL; Shi XH; Jiang GL; Wang Y Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):123-9. PubMed ID: 15337547 [TBL] [Abstract][Full Text] [Related]
5. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer]. Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788 [TBL] [Abstract][Full Text] [Related]
6. A phase III study of late course accelerated hyperfractionated radiotherapy versus conventionally fractionated radiotherapy in patients with nasopharyngeal carcinoma. Pan ZQ; He XY; Guo XM; Ye M; Zhang Z; He SQ; Liu TF Am J Clin Oncol; 2012 Dec; 35(6):600-5. PubMed ID: 22134512 [TBL] [Abstract][Full Text] [Related]
7. Comparison between continuous accelerated hyperfractionated and late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma. Wang Y; Shi XH; He SQ; Yao WQ; Wang Y; Guo XM; Wu GD; Zhu LX; Liu TF Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):131-6. PubMed ID: 12182982 [TBL] [Abstract][Full Text] [Related]
8. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949 [TBL] [Abstract][Full Text] [Related]
9. Late course accelerated hyperfractionated radiotherapy of nasopharyngeal carcinoma (LCAF). He XY; Liu TF; He SQ; Huan SL; Pan ZQ Radiother Oncol; 2007 Oct; 85(1):29-35. PubMed ID: 17889386 [TBL] [Abstract][Full Text] [Related]
10. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428 [TBL] [Abstract][Full Text] [Related]
11. [Late course three-dimensional conformal radiotherapy in patients with stage III non-small cell lung cancer]. Wang XC; Wang SY; Yang S; Ding Y; Shang Y Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):726-8. PubMed ID: 15958322 [TBL] [Abstract][Full Text] [Related]
12. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Shi XH; Yao W; Liu T Radiother Oncol; 1999 Apr; 51(1):21-6. PubMed ID: 10386713 [TBL] [Abstract][Full Text] [Related]
13. Three-dimensional conformal radiation therapy for squamous cell carcinoma of the esophagus: a prospective phase I/II study. Wu KL; Chen GY; Xu ZY; Fu XL; Qian H; Jiang GL Radiother Oncol; 2009 Dec; 93(3):454-7. PubMed ID: 19919886 [TBL] [Abstract][Full Text] [Related]
14. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549 [TBL] [Abstract][Full Text] [Related]
15. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243 [TBL] [Abstract][Full Text] [Related]
16. [Study on clinical application of multiple fractions per day radiation therapy with concomitant boost technique for esophageal cancer]. Kikuchi Y Hokkaido Igaku Zasshi; 1993 Jul; 68(4):537-56. PubMed ID: 8340051 [TBL] [Abstract][Full Text] [Related]
17. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Horwich A; Dearnaley D; Huddart R; Graham J; Bessell E; Mason M; Bliss J Radiother Oncol; 2005 Apr; 75(1):34-43. PubMed ID: 15878099 [TBL] [Abstract][Full Text] [Related]
18. Californium-252 (252Cf) versus conventional gamma radiation in the brachytherapy of advanced cervical carcinoma long-term treatment results of a randomized study. Tacev T; Ptácková B; Strnad V Strahlenther Onkol; 2003 Jun; 179(6):377-84. PubMed ID: 12789463 [TBL] [Abstract][Full Text] [Related]
19. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346 [TBL] [Abstract][Full Text] [Related]